Bibliography
(1) Steegmann JL et al. 2016. European Leukemia Net Recommendations for the management and avoidance of adverse events of treatment in CML (ocular events chapter). Leukemia; 30(8): 1648–1671
(2) Davis ME et al. 2016. Ocular toxicity of TKIs. Oncol Nurs Forum; 43(2): 235-243
(3) Kwon SI, Lee DH, Kim YJ. 2008. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol; 52(4): 331–333
(4) DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. 2012. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci; 89(10): e16–e22
(5) Napolitano M, Santoro M, Mancuso S, Carlisi M, Raso S, Tarantino G, Accurso V, Siragusa S. 2017. Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. Clin Case Rep; 5(10): 1573–1575
(6) Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B. 2014. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Survey of Ophthalmology; 59:498–502
(7) Renouf DJ, Velazquez JP, Simpron, Siu LL, Bedard PL. 2012. Ocular toxicity of targeted therapies. Journal of Clinical Oncology; 30:3277–3286
(8) Breccia M et al. 2008. Ocular side effects in CML patients treated with Imatinib. Leuk Res; 32(7):1022-5
(9) Govind BK et al. 2007. IM-induced optic neuritis in a patient of chronic myeloid leucemia. Int Ophthamol; 27:43-4
(10) Fu C et al. 2017. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget, 8, (35): 58709-58727
(11) Moore DC et al. 2018. Nilotinib-induced ocular toxicity: a case report. Am J Ther; 25(5):e570-e571
(12) Sotelo-Monge K et al. 2015. Ocular neuropathy secondary to dasatinib in the treatment of CML case. Saudi J Ophtalmology; 29(3): 227-231
(13) Cortes JE et al. 2018. Management of adverse events associated with bosutinib treatment of CP-CML: expert pad review. J HematolOncol; 27;11(1):143
(14) A multicentre phase 3 open-label study of Bosutinib versus Imatinib in adult patients with newly diagnosed CP-CML. ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT02130557
(15) Cortes JE et al. 2018. Bosutinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J ClinOncol; 20;36(3):231-237